Prime Medicine, Inc.

NasdaqGM PRME

Prime Medicine, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 61.49 M

Prime Medicine, Inc. Net Cash Used For Investing Activities is USD 61.49 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 269.57% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Prime Medicine, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -36.26 M, a -70.60% change year over year.
Prime Medicine, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -21.25 M.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGM: PRME

Prime Medicine, Inc.

CEO	Dr. Keith Michael Gottesdiener M.D., Ph.D.
IPO Date	Oct. 20, 2022
Location	United States
Headquarters	21 Erie Street
Employees	234
Sector	Healthcare
Industries Biotechnology

Description

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years